AR022318A1 - USE OF IMIDAZO [1,5-A] -PIRIDO [3,2-E] -PIRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 TO TREAT ERECTILE DYSFUNCTION, AS INHIBITORS OF PHOSPHODIESTERASE 3 AND PHOSPHODESTERASA 5 TO TREAT LA CARD PULMONARY HYPERTONIA AND ANGIOPATIAS, WHICH ARE ACCOMPANIED - Google Patents
USE OF IMIDAZO [1,5-A] -PIRIDO [3,2-E] -PIRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 TO TREAT ERECTILE DYSFUNCTION, AS INHIBITORS OF PHOSPHODIESTERASE 3 AND PHOSPHODESTERASA 5 TO TREAT LA CARD PULMONARY HYPERTONIA AND ANGIOPATIAS, WHICH ARE ACCOMPANIEDInfo
- Publication number
- AR022318A1 AR022318A1 ARP000100246A ARP000100246A AR022318A1 AR 022318 A1 AR022318 A1 AR 022318A1 AR P000100246 A ARP000100246 A AR P000100246A AR P000100246 A ARP000100246 A AR P000100246A AR 022318 A1 AR022318 A1 AR 022318A1
- Authority
- AR
- Argentina
- Prior art keywords
- 14aryl
- alkyl
- several times
- inhibitors
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se trata de la utilizacion de imidazo [1,5-a] - pirido [3,2 -e] pirazinonas de la formula 1 como inhibidores de la fosfodiesterasa 5 para el tratamiento dela disfuncion eréctil (impotencia), la utilizacion de imidazo [1,5 -a] pirido[3,2-e]-pirazinon as de la formula 1 como inhibidores duales de la fosfodiesterasa3 y de la fosfodiesterasa5 para el tratamiento de insuficiencia cardíaca,hipertonía pulmonar y angiopatías, que están acompanadas con una irrigacion sanguíneareducida,y procedimientos p ara su preparacion. Dichos compuestos responden a la formula 1 donde A es O, R1, R2, R3 pueden ser iguales o diferentes y puedensignificar hidrogeno, así como C1-8-alquilo, de cadena recta o de cadena ramificada, llegado el caso,sustituido una o var ias veces con -OH, -SH, -NH2, -NHC1-6-alquilo, -N(C1-6-alquilo)2, NHC6-14arilo, -N(C6-14arilo)2, -N(C1-6alquil)(C6-14arilo), -NO2, -CN, COOH, -COOC1-5alquilo, -(C=O)C1-5alquilo, -F, -Cl, -Br, I,-O--C1-6-alquilo-O -C6-14-arilo,-S-C1-6-alquilo, -S-C6- 14arilo, OSO2C1-6alquilo, -OSO2C6-14arilo, carbociclos saturados mono, bi o tricíclicos o insaturados unao varias veces con 3-14 miembros del anillo, heterociclos saturados mono, bi o tricíclicos o insaturados una o variasveces con 5-15 miembros del anillo y 1-6heteroátomos, que son preferentemente n; O y S, C2-8 alquenilo, insaturado una o varias veces, de cadena recta o de cadena ramificada, llegado el caso,sustituio una o varias veces con -OH,-SH,-NH2,-NHC1-6-alquilo,_N(C1-6-alquilo)2,-NHC6-14arilo,-N(C6-14arilo)2,-N(C1-6alquil)(C6-14arilo),-NO2,-CN,-COOH,-COOC1-5alquilo,-(C=O)C1-5alquilo,-F,Cl,-Br,-I,-O-C1-6-alquilo,-O-C6-14-arilo,-S-C1-6-alquilo,-S-C6-14arilo,-OSO2C1-6alquilo,-OSO2C6-14arilo, carbociclos saturadosbi o tricíclicos oi nsaturados una o varias veces con 3-14 miembros del anillo, heterociclos saturados mono, bi o tricíclicos o insaturados una o varias vecescon 5-15 miembros del anillo y 1-6 heteroátomos, que preferentemente son N, O y S, -C2-8-alquinilo,insaturado u na o varias veces, de cadena recta o de cadenaramificada, llegado el caso, sustituido una o varias veces con -OH, -SH, -NH2, -NHC1-6-alquilo, N(C1-6-alquilo)2, NHC6-14arilo, -N(C6-14arilo)2, -N(C1-6alquil)It concerns the use of imidazo [1,5-a] - pyrido [3,2-e] pyrazinones of formula 1 as phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction (impotence), the use of imidazo [1 , 5-a] pyrido [3,2-e] -pyrazinon ace of formula 1 as dual inhibitors of phosphodiesterase3 and phosphodiesterase5 for the treatment of heart failure, pulmonary hypertonia and angiopathies, which are accompanied by a reduced blood supply, and procedures for its preparation. Said compounds respond to formula 1 where A is O, R1, R2, R3 can be the same or different and can mean hydrogen, as well as C1-8-alkyl, straight chain or branched chain, where appropriate, substituted one or var sometimes with -OH, -SH, -NH2, -NHC1-6-alkyl, -N (C1-6-alkyl) 2, NHC6-14aryl, -N (C6-14aryl) 2, -N (C1-6alkyl) (C6-14aryl), -NO2, -CN, COOH, -COOC1-5alkyl, - (C = O) C1-5alkyl, -F, -Cl, -Br, I, -O - C1-6-alkyl- O-C6-14-aryl, -S-C1-6-alkyl, -S-C6- 14aryl, OSO2C1-6alkyl, -OSO2C6-14aryl, mono, bi or tricyclic saturated or unsaturated carbocycles one or several times with 3-14 members of the ring, mono, bi or tricyclic or unsaturated saturated heterocycles one or more times with 5-15 ring members and 1-6 heteroatoms, which are preferably n; O and S, C2-8 alkenyl, unsaturated once or several times, straight chain or branched chain, if necessary, substituted once or several times with -OH, -SH, -NH2, -NHC1-6-alkyl, _N (C1-6-alkyl) 2, -NHC6-14aryl, -N (C6-14aryl) 2, -N (C1-6alkyl) (C6-14aryl), - NO2, -CN, -COOH, -COOC1-5alkyl, - (C = O) C1-5alkyl, -F, Cl, -Br, -I, -O-C1-6-alkyl, -O-C6-14-aryl, -S-C1-6-alkyl, -S -C6-14aryl, -OSO2C1-6alkyl, -OSO2C6-14aryl, saturated carbobicycles or tricyclics saturated once or several times with 3-14 ring members, saturated mono, bi or tricyclic heterocycles or unsaturated once or several times with 5-15 members of the ring and 1-6 heteroatoms, which are preferably N, O and S, -C2-8-alkynyl, unsaturated or na or several times, straight chain or branched chain, if necessary, substituted once or several times with -OH , -SH, -NH2, -NHC1-6-alkyl, N (C1-6-alkyl) 2, NHC6-14aryl, -N (C6-14aryl) 2, -N (C1-6alkyl)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1999102082 DE19902082A1 (en) | 1999-01-20 | 1999-01-20 | New and known imidazo(1,5-a)pyrido(3,2-e)pyrazinone derivatives, useful as phosphodiesterase 5 inhibitors for treating erectile dysfunction |
| DE1999161302 DE19961302A1 (en) | 1999-12-18 | 1999-12-18 | Treatment of erectile dysfunction using new or known imidazo(1,5-a)pyrido(3,2-e)pyrazinones as phosphodiesterase inhibitors, some of which are also useful for treating cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022318A1 true AR022318A1 (en) | 2002-09-04 |
Family
ID=26051406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100246A AR022318A1 (en) | 1999-01-20 | 2000-01-19 | USE OF IMIDAZO [1,5-A] -PIRIDO [3,2-E] -PIRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 TO TREAT ERECTILE DYSFUNCTION, AS INHIBITORS OF PHOSPHODIESTERASE 3 AND PHOSPHODESTERASA 5 TO TREAT LA CARD PULMONARY HYPERTONIA AND ANGIOPATIAS, WHICH ARE ACCOMPANIED |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1144410A2 (en) |
| JP (1) | JP2002535330A (en) |
| KR (1) | KR20010101603A (en) |
| CN (1) | CN1344268A (en) |
| AR (1) | AR022318A1 (en) |
| AU (1) | AU2291200A (en) |
| BG (1) | BG105714A (en) |
| BR (1) | BR0007613A (en) |
| CA (1) | CA2296224A1 (en) |
| CO (1) | CO5190700A1 (en) |
| CZ (1) | CZ20012627A3 (en) |
| EA (1) | EA200100792A1 (en) |
| EE (1) | EE200100377A (en) |
| HU (1) | HUP0105132A3 (en) |
| ID (1) | ID29790A (en) |
| IL (1) | IL144156A0 (en) |
| IS (1) | IS5987A (en) |
| LT (1) | LT2001078A (en) |
| LV (1) | LV12793B (en) |
| NO (1) | NO20013334D0 (en) |
| SK (1) | SK10322001A3 (en) |
| TR (1) | TR200102121T2 (en) |
| WO (1) | WO2000043392A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US20050107394A1 (en) * | 2001-12-17 | 2005-05-19 | Ardeschir Ghofrani | Novel use of selective pde5 inhibitors |
| FR2835741B1 (en) * | 2002-02-12 | 2006-05-05 | Oreal | NOVEL 6-ALCOXY-2,3-DIAMINOPYRIDINE COUPLINGS USEFUL FOR DYING KERATIN FIBERS |
| US6916345B2 (en) | 2002-02-12 | 2005-07-12 | L'oreal S.A. | 6-alkoxy-2,3-diaminopyridine couplers for dyeing keratin fibres |
| DE10325813B4 (en) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxis and / or therapy in portal hypertension |
| US8299083B2 (en) | 2004-08-17 | 2012-10-30 | The Johns Hopkins University | PDE5 inhibitor compositions and methods for treating cardiac indications |
| KR101563103B1 (en) * | 2006-12-13 | 2015-10-23 | 아스카 세이야쿠 가부시키가이샤 | Quinoxaline derivative |
| WO2009070583A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| JP2011505366A (en) | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10 |
| EP3121178B1 (en) | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
| US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
| JP5842640B2 (en) * | 2012-01-31 | 2016-01-13 | 株式会社東洋新薬 | Phosphodiesterase 3 inhibitor |
| US10005789B2 (en) | 2014-08-07 | 2018-06-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016022825A1 (en) * | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2971969T3 (en) | 2015-07-07 | 2024-06-10 | H Lundbeck As | PDE9 Inhibitors with Imidazopyrazinone Backbone for the Treatment of Peripheral Diseases |
| HRP20240363T1 (en) | 2018-05-25 | 2024-06-07 | Cardurion Pharmaceuticals, Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imidazo [1,5- a] pyrazin-8-one |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| DE19510965A1 (en) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation |
-
2000
- 2000-01-14 HU HU0105132A patent/HUP0105132A3/en unknown
- 2000-01-14 EE EEP200100377A patent/EE200100377A/en unknown
- 2000-01-14 KR KR1020017009112A patent/KR20010101603A/en not_active Application Discontinuation
- 2000-01-14 SK SK1032-2001A patent/SK10322001A3/en unknown
- 2000-01-14 EA EA200100792A patent/EA200100792A1/en unknown
- 2000-01-14 ID IDW00200101592A patent/ID29790A/en unknown
- 2000-01-14 CN CN00805307A patent/CN1344268A/en active Pending
- 2000-01-14 EP EP00901561A patent/EP1144410A2/en not_active Withdrawn
- 2000-01-14 IL IL14415600A patent/IL144156A0/en unknown
- 2000-01-14 AU AU22912/00A patent/AU2291200A/en not_active Abandoned
- 2000-01-14 TR TR2001/02121T patent/TR200102121T2/en unknown
- 2000-01-14 BR BR0007613-9A patent/BR0007613A/en not_active Application Discontinuation
- 2000-01-14 JP JP2000594808A patent/JP2002535330A/en active Pending
- 2000-01-14 WO PCT/EP2000/000260 patent/WO2000043392A2/en not_active Application Discontinuation
- 2000-01-14 CZ CZ20012627A patent/CZ20012627A3/en unknown
- 2000-01-19 CA CA002296224A patent/CA2296224A1/en not_active Abandoned
- 2000-01-19 CO CO00002747A patent/CO5190700A1/en not_active Application Discontinuation
- 2000-01-19 AR ARP000100246A patent/AR022318A1/en unknown
-
2001
- 2001-06-29 IS IS5987A patent/IS5987A/en unknown
- 2001-07-05 NO NO20013334A patent/NO20013334D0/en not_active Application Discontinuation
- 2001-07-17 BG BG105714A patent/BG105714A/en unknown
- 2001-07-19 LV LV010109A patent/LV12793B/en unknown
- 2001-07-19 LT LT2001078A patent/LT2001078A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010101603A (en) | 2001-11-14 |
| NO20013334L (en) | 2001-07-05 |
| SK10322001A3 (en) | 2002-07-02 |
| EA200100792A1 (en) | 2002-10-31 |
| HUP0105132A3 (en) | 2002-12-28 |
| WO2000043392A3 (en) | 2000-09-28 |
| WO2000043392A2 (en) | 2000-07-27 |
| IS5987A (en) | 2001-06-29 |
| IL144156A0 (en) | 2002-05-23 |
| CN1344268A (en) | 2002-04-10 |
| LT2001078A (en) | 2002-08-26 |
| HUP0105132A2 (en) | 2002-05-29 |
| NO20013334D0 (en) | 2001-07-05 |
| AU2291200A (en) | 2000-08-07 |
| EP1144410A2 (en) | 2001-10-17 |
| ID29790A (en) | 2001-10-11 |
| LV12793B (en) | 2002-05-20 |
| CO5190700A1 (en) | 2002-08-29 |
| EE200100377A (en) | 2002-10-15 |
| CA2296224A1 (en) | 2000-07-20 |
| BR0007613A (en) | 2001-10-30 |
| LV12793A (en) | 2002-02-20 |
| BG105714A (en) | 2002-02-28 |
| TR200102121T2 (en) | 2002-01-21 |
| JP2002535330A (en) | 2002-10-22 |
| CZ20012627A3 (en) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022318A1 (en) | USE OF IMIDAZO [1,5-A] -PIRIDO [3,2-E] -PIRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 TO TREAT ERECTILE DYSFUNCTION, AS INHIBITORS OF PHOSPHODIESTERASE 3 AND PHOSPHODESTERASA 5 TO TREAT LA CARD PULMONARY HYPERTONIA AND ANGIOPATIAS, WHICH ARE ACCOMPANIED | |
| GT200000168A (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS. | |
| GT200000069A (en) | USEFUL HETEROCICLIC DERIVATIVES AS ANTI-TARGET AGENTS | |
| PE20120121A1 (en) | IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS | |
| AR094185A2 (en) | PHOSPHORIC ACID SALT OF A DIPEPTIDIL PEPTIDASA-IV INHIBITOR | |
| MY128479A (en) | (beta)-carboline derivatives useful as inhibitors of phosphodiesterase | |
| PE20040897A1 (en) | 8- [3-AMINO-PIPERIDIN-1-IL] -XANTHINES AND THEIR PREPARATION AS MEDICINES | |
| EP2156864A3 (en) | Hair dye composition comprising unsoluble compounds and uses thereof | |
| MX9203369A (en) | DERIVATIVES OF IMIDAZO [1,5-A] PIRIDINA AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| DE50302975D1 (en) | NEW XANTHINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DRUGS | |
| SV2003001173A (en) | 1-RENT OR 1-CICLOALQUIL-TRIAZOLO [4,3-A] QUINAZOLIN-5- WAVES AS PHOSPHODIESTERASE INHIBITORS | |
| BR0006380A (en) | 2-Aminoalkyl-1,4-diamino-benzene derivatives and dyeing agents containing these compounds | |
| PE20030208A1 (en) | INDIRUBIN DERIVATIVES CONTAINING SULFUR, THEIR PREPARATION AND USE | |
| PE20030664A1 (en) | TRIAZOLO [4,3-a] PIRIDO [2,3-d] PYRIMIDIN-5-ONA DERIVATIVES, COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE | |
| ES2101858T3 (en) | GENESERINE DERIVATIVES AS CHOLINESTERASE INHIBITORS. | |
| TR199902495T2 (en) | Bile�imler. | |
| BRPI0507616A (en) | keratin dyeing compounds, keratin dyeing compositions comprising such compounds and use of such compositions | |
| ES2175386T3 (en) | DERIVATIVES OF 2,3-BENZODIAZEPIN AND ITS USE AS AMPA RECEIVER INHIBITORS. | |
| Xia et al. | Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido [1, 2-e] purin-4 (3H)-one derivatives | |
| CA2445625A1 (en) | Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives | |
| ES2059931T3 (en) | PROCEDURE FOR THE TREATMENT OF HYPERTROPHY AND CARDIAC HYPERPLASIA AS WELL AS VASCULAR. | |
| MXPA03008250A (en) | Novel diaminopyrazole derivatives and dyes containing said compounds. | |
| TR200103237T2 (en) | Imidazodiazepine derivative | |
| AR015518A1 (en) | USE OF TIADIAZOLO PYRIDINE DERIVATIVES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MODULATED BY INHIBITION OF THE PHOSPHODIESTERASE (S) | |
| MX9306563A (en) | DERIVATIVES OF IMIDAZOPIRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM. |